Ceangail le linn

EU

#EAPM - Bailíonn na ballstáit na moltaí #HTA is déanaí

ROINN:

foilsithe

on

Úsáidimid do shíniú suas chun ábhar a sholáthar ar bhealaí ar thoiligh tú leo agus chun ár dtuiscint ortsa a fheabhsú. Is féidir leat díliostáil ag am ar bith.


With its round table on the ongoing issues of health technology assessment (HTA) coming up on Wednesday 7 November, the European Alliance for Personalised Medicine is positioning itself and stakeholders in order to tackle the issues involved, which will also be discussed in depth at EAPM’s Congress in Milan (26-28 November),
Scríobhann Chomhghuaillíocht Eorpach do Pearsanta Leigheas (EAPM) Stiúrthóir Feidhmiúcháin Denis Horgan.

The Brussels meeting, to be co-hosted by Malta’s permanent representation to the EU, aims to move the whole debate forward and, alongside Malta, Austrian MEP Paul Rubig, whose country holds the EU's rotating presidency until the end of the year, will act as co-host.

Health-care representatives from Austria, Cyprus, Slovakia, Slovakia, Sweden, Hungary, Netherlands, Lithuania, Croatia, Greece, Germany and, of course, Malta, will be present while representatives from industry and patient groups will also take part.

The meeting will assess where Europe currently stands with regards to the Commission proposal on HTA, as well as addressing direct concerns and opportunities. 

The round table will also look into the benefits arising from the proposed ew legislation on HTA while focusing on ways to enable bringing innovation into health-care systems in a truly practical sense.

The gathering will also zoom in on specific provisions and elements of the legislation proposal, in order to have a meaningful and practical discussion among key players, including EUnetHTA.

The round table will, in fact, feature presentations from representatives of EUnetHTA - which performs the function of the scientific and technical cooperation of the HTA Network.

Aiseolas

The meeting comes against a backdrop that has seen the current rotating EU presidency, Austria, propose a compromise to member states on sections of the HTA issue.

The Commission’s plans have caused something of a ruckus due to its and the European Parliament’s backing for mandatory Europe-wide HTA co-operation.

Austria served up its suggestions to national health delegates in a meeting on Friday and, while still backing the mandatory elements, it underlined the right of member states to add to the EU-wide efforts on a country-by-country basis.

Given that member states have competence for health care under the Treaties, several states - including heavyweights Germany and France - feel that the Commission is over-stretching its powers. However, the EU’s legal eagles have said that it isn’t.

Austria produced a document unveiled in Vienna saying that member states “shall use the joint clinical assessment reports” in their own HTA processes, and “shall not duplicate” the joint work.

However, individual countries may go it alone with work to “complement” the joint efforts.

Additionally, they can also “take into account other clinical data and evidence which did not form part of the joint clinical assessment”, plus they can perform “non-clinical assessments on the same health technology”.

In a blow to the Commission, however, Austria has pushed for chopping one section of the Berlaymont’s plans, saying it feels the Commission’s wish to approve or reject member states’ proposals on HTA on top of the joint work needs to be put aside.

Austria proposes that member states “shall remain responsible for the national health technology assessment process and shall draw their own overall conclusions on the added value of the health technologies concerned based on the joint clinical assessment report, and any complementary analyses and non-clinical assessment”.

As mentioned above, the broad issue will come under the microscope at EAPM’s November Congress, for which you can register anseo.  To view the programme, please cliceáil anseo.

Also key to the agenda at the Milan event is embedding healthcare innovation, incentives and investment through personalised medicine. The Alliance has called this process “3i - innovation, investment and incentives”, saying it is geared towards encouraging investment in health innovation.

This starts as of now and will take into account the European Parliamentary elections of next year, as well as the formulation of a new Commission not long afterwards.

The programme dovetails with EAPM's ongoing ‘SMARTinitiative, which stands for Smaller member States And Regions Together, and involves an on-the-ground approach and presence to help to integrate personalised-medicine concepts into national health-care systems.

Innovation (and the incentives for it) are key to health and wealth in the current EU-28 and will be even more important after the UK leaves at the end of March 2019.

Early dialogue between technology developers, regulatory, health technology assessment and, where relevant, pricing bodies will promote innovation and quicker access to medicines at affordable prices, to the benefit of patients.

Perhaps surprisingly, there are far too few forums that allow this necessary inter-stakeholder dialogue, with the result that the people who need the fastest results most - namely the patients - end up losing out. The Alliance provides, therefore, a vital one-stop-shop.

EAPM's over-arching plan for the 3i project, according to the Alliance’s Executive Director Denis Horgan, is ultimately to “highlight the role of innovation at the same time as showcasing examples of innovative development in personalised medicine at grass-roots level across member states".

“This is a key focus of the Congress and of our work going forward,” he said.

Comhroinn an t-alt seo:

Foilsíonn Tuairisceoir an AE ailt ó fhoinsí éagsúla seachtracha a chuireann raon leathan dearcthaí in iúl. Ní gá gur seasaimh Tuairisceoir an AE iad na seasaimh a ghlactar sna hairteagail seo.

trending